The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-11—ai-driven-antibody-discovery-at-evotec-6098
